Psychedelic Drugs Top Companies and Strategic Involvements

Psychedelic Drugs Market Top Companies and Their Offerings

What are the Recent Developments in the Psychedelic Drugs Market?

• In April 2026, along with President Donald J. Trump's executive order to accelerate the development and potential approval of psychedelic-based therapies, the FDA announced support for the development of serotonin 2A agonists and related products. Moreover, the FDA has issued national priority vouchers to 3 companies researching methylone for PTSD, psilocybin for treatment-resistant depression, and psilocybin for major depressive disorder.
• In May 2026, the formation of EPIK Biosciences as a psychedelic drug development company was announced, which will focus on the development of a portfolio of proprietary ketamine-based therapies. Advanced co-delivery formulations and synergistic combination medications targeting mental health disorders, substance use disorders, and severe/chronic pain are being developed by the company.

Psychedelic Drugs Market Value Chain Analysis

R&D

• The R&D of the psychedelic drugs focuses on the development of next-generation short-acting synthetic analgesics with enhanced safety profiles.
• Key players: Compass Pathways, Helus Pharma, Definium Therapeutics.

Clinical Trials and Regulatory Approvals

• The safety, optimal dosage, efficacy, and duration of psychoactive effects are evaluated in the clinical trials and regulatory approvals of the psychedelic drugs.
• Key players: Compass Pathways, Helus Pharma, Definium Therapeutics.

Patient Support and Services

• Rigorous pre-treatment preparation, post-session integration, and in-session monitoring are provided in the patient support and services of the psychedelic drugs.
• Key players: Compass Pathways, Helus Pharma, Numinus Wellness.

Market Growth

The global psychedelic drugs market size was estimated at USD 5.82 billion in 2025 and is predicted to increase from USD 6.68 billion in 2026 to approximately USD 23.14 billion by 2035, expanding at a CAGR of 14.8% from 2026 to 2035.